Identifying biosimilar side effects: Infliximab-dyyb-associated subcorneal pustular dermatosis

• Type of Material: Article
• Authors: Maria Amoreth R Gozo, U.S.S. Anchorage, Naval Base San Diego, United States Navy, San Diego; Iviensan F Manalo, Emory University; Tunisia Cornelius, Emory Decatur Hospital
• Language: English
• Date: 2021-06-01
• Publisher: Elsevier
• Publication Version: Final Published Version
• Copyright Statement: © 2020 Published by Elsevier Inc. on behalf of Women's Dermatologic Society.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.ijwd.2020.12.004
• Title of Journal or Parent Work: International Journal of Women's Dermatology
• Volume: 7
• Issue: 3
• Start Page: 367
• End Page: 368
• Grant/Funding Information: None
• Keywords: clinical trials; biosimilar; dermatology clinic
• Research Categories: Health Sciences, Medicine and Surgery

Abstract

Biologics such as infliximab account for a growing multibillion-dollar industry, treating a myriad of inflammatory conditions ranging from psoriasis to inflammatory bowel disease. As patents for these medications expire, a growing market is surfacing to derive highly similar but more affordable therapies, known as biosimilars (McKinnon and Ward, 2016). Because the approval process of biosimilars does not require the same extensive clinical trial phases as the originators, we highlight that informational gaps exist on the postmarking side effects of biosimilars (Yamauchi et al., 2018). The following case presents an example of a new-onset rash in the setting of initiating biosimilar infliximab-dyyb treatment.